CRADA Awarded Under Recent Rapid Innovation
Fund Contract; Project to Demonstrate Hand-held DNA Detection Kits
to Drive Adoption of DNA-based Supply Chain Security
Applied DNA Sciences, Inc. (“Applied DNA”, “the
Company”)(NASDAQ:APDN), is proud to announce the signing of a
Cooperative Research and Development Agreement (“CRADA”) with the
U.S. Army Research, Development and Engineering Command’s Edgewood
Chemical Biological Center (“ECBC”) to study the commercialization
of ECBC’s innovative rapid, in-field DNA microarray technology for
use in military and commercial supply chains. ECBC is the nation’s
primary Department of Defense (“DoD”) technical research
organization for non-medical chemical and biological warfare
defense.
Under the terms of the CRADA, a cooperative effort under the
recently-announced Defense Logistics Agency Rapid Innovation Fund
award secured by Applied DNA in June 2017, ECBC’s subject matter
experts and Applied DNA’s science team will cooperatively study the
feasibility of commercializing ECBC’s in-field DNA detection
technology in varied supply chains. ECBC’s hand-held in-field DNA
microarray technology allows for detection of a DNA taggant within
a few minutes. The project goal is to demonstrate the system with
Applied DNA’s taggants introduced into standard inks or varnishes
or onto other surfaces, without the need for DNA amplification or
other sample preparation, thus greatly simplifying in-field DNA
detection.
“Rapid, hand-held in-field DNA detection has long been a goal of
ours and is essential to the long-term growth of our technology
platform,” stated Dr. James Hayward, president and CEO of Applied
DNA. “We are honored to work with the U.S. Army through ECBC to
study the commercialization of the ECBC’s innovative in-field DNA
detection technology as a complement to our DNA authentication
products for supply chain integrity capable of rapid detection
anywhere, anytime, for global supply chains.”
Continued Dr. Hayward, “This mutually beneficial cooperative
research and development project parallels our ongoing partnership
with several DoD agencies and reflects our continued efforts to
commercialize technologies made available under our ongoing DoD
R&D contracts. We believe that the ECBC’s technology is
extremely promising in this regard and are excited to work
alongside it on this next generation data capture.”
About the U.S. Army Research, Development and Engineering
Command’s Edgewood Chemical Biological Center
ECBC possesses an unrivaled chemical biological research and
development infrastructure with scientists, engineers, technicians
and specialists located at four different sites in the United
States: Edgewood Area of Aberdeen Proving Ground, Md., Pine Bluff,
Ark., Rock Island, Ill., and Dugway Proving Ground, Utah.
ECBC has a unique role in technology development that cannot be
duplicated by private industry or research universities. It fosters
research, development, testing, and application of technologies for
protecting warfighters, first responders and the nation from
chemical and biological warfare agents. ECBC is currently
developing better ways to remotely detect these chemical and
biological materials – before the warfighter or first responder
ever enters the threat zone. ECBC is also developing a new
generation of technologies to counter everything from homemade
explosives to biological aerosols to traditional and
non-traditional chemical hazards.
About Applied DNA
Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and DNA mass production for
diagnostics and therapeutics.
We make life real and safe by providing innovative,
molecular-based technology solutions and services that can help
protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft,
counterfeiting, fraud and diversion. The proprietary DNA-based
“CertainT™” platform can be used to identify, tag, test, and track
products, to help assure authenticity, origin, traceability,
sustainability and quality of products.
SigNature® DNA describes the core technology ingredient that is
at the heart of a family of uncopiable, security and authentication
solutions such as SigNature® T and fiberTyping®, targeted toward
textiles and apparel, BackTrac™ and DNAnet®, for anti-theft and
loss prevention, and digitalDNA®, providing powerful
track-and-trace. All provide a forensic chain of evidence, and can
be used to prosecute perpetrators. Applied DNA Sciences is also
engaged in the large-scale production of specific DNA sequences
using the polymerase chain reaction.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under the symbol
APDN, and its warrants are listed under the symbol APDNW.
Forward Looking Statements
The statements made by APDN in this press release may be
"forward-looking" in nature within the meaning of the Private
Securities Litigation Act of 1995. Forward-looking statements
describe APDN's future plans, projections, strategies and
expectations, and are based on assumptions and involve a number of
risks and uncertainties, many of which are beyond the control of
APDN. Actual results could differ materially from those projected
due to our short operating history, limited financial resources,
limited market acceptance, market competition and various other
factors detailed from time to time in APDN's SEC reports and
filings, including our Annual Report on Form 10-K filed on December
6, 2016, and our subsequent quarterly reports on Form 10-Q filed on
February 9, 2017, May 11, 2017 and August 10, 2017, which are
available at www.sec.gov. APDN, undertakes no obligation to update
publicly any forward-looking statements to reflect new information,
events or circumstances after the date hereof to reflect the
occurrence of unanticipated events, unless otherwise required by
law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170912005094/en/
Investors:LHA Investor RelationsSanjay M. Hurry,
212-838-3777shurry@lhai.comorMedia:Dian Griesel Int’lSusan
Forman, 212-825-3210sforman@dgicomm.comorProgram:Applied
DNAJanice Meraglia,
631-240-8821janice.meraglia@adnas.comweb:
www.adnas.comtwitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024